z-logo
Premium
In vitro photodynamic therapy against Foncecaea pedrosoi and Cladophialophora carrionii
Author(s) -
Lyon Juliana Pereira,
Moreira Leonardo Marmo,
Dutra de Carvalho Vanessa Silva,
dos Santos Fabio Vieira,
de Lima Carlos José,
de Resende Maria Aparecida
Publication year - 2013
Publication title -
mycoses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.13
H-Index - 69
eISSN - 1439-0507
pISSN - 0933-7407
DOI - 10.1111/j.1439-0507.2012.02226.x
Subject(s) - photodynamic therapy , chromoblastomycosis , methylene blue , microbiology and biotechnology , spore , in vitro , agar , medicine , biology , chemistry , bacteria , biochemistry , genetics , organic chemistry , photocatalysis , catalysis
Summary Photodynamic therapy (PDT) has been originally developed for cancer treatment, but recently, it has been successfully employed against microorganisms, including fungi. Chromoblastomycosis is a subcutaneous fungal infection that is recalcitrant to conventional antifungal drug therapy. The most frequent species involved are Foncecaea pedrosoi and Cladophialophora carrionii . The present study aimed to verify the efficacy in vitro of PDT employing methylene blue (MB) as a photosensitiser and Light emmiting diode (LED) (InGaAl) as the light source. Methylene blue at the concentrations of 16, 32 and 64 μg/mL and LED (InGalP) were employed for 15 min against spores of two isolates of F. pedrosoi and two isolates of C. carrionii . The spores were plated on Sabouraud Dextrose agar and the number of colony forming units was counted after 7–10 days of incubation at 37 °C. The PDT with MB and LED was efficient in reducing the growth of all samples tested. Better results were obtained for the concentration of 32 μg/mL of MB. The treatment proved to be highly effective in killing the samples of F. pedrosoi and Cladophialophora pedrosoi tested in vitro . PDT arises as a promising alternative for the treatment of this subcutaneous infection.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here